 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- | Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Preclinical, Journal: A Novel Self-Assembled Paclitaxel Nanodispersion Facilitates Rapid In-Vitro/In-Vivo Dissociation and Protein Binding. (Pubmed Central) - Dec 6, 2024
The results present a novel formulation design that forms sponge-like coacervate nanoparticle due to complimentary interactions of the excipients that otherwise are unable to self-assemble under similar conditions of dilution. This alternative formulation solves the limitations of currently marketed PtX products and can provide its effective delivery in clinical settings.
- || Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Clinical, P1 data, PK/PD data, Journal, Combination therapy: A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. (Pubmed Central) - Sep 19, 2021
This study demonstrated the safety and stable pharmacokinetics of PICN as a monotherapy and in combination with carboplatin. Single-agent PICN showed promising antitumor activity in advanced BTCs, warranting further studies to investigate its role in gastrointestinal cancers.
- ||| Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma
Clinical, FDA event: SPARC receives complete response letter from @US_FDA for Taclantis; @US_FDA sets a review date for @SunPharma_Live's Taclantis application in Feb 2020, learns @ekta_batra (Twitter) - Feb 12, 2020
- Odomzo (sonidegib) / Sun Pharma, Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma, Abraxane (albumin-bound paclitaxel) / Celgene, Otsuka
Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2340;
P1/2
Clinical trial identification: NCT02358161. Legal entity responsible for the study: J.W. Wilmink.
- || Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Enrollment change: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Dec 11, 2018
P1, N=57, Completed, Sponsor: Sun Pharma Advanced Research Company Limited
Legal entity responsible for the study: J.W. Wilmink. N=30 --> 57
- | Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Trial completion, Trial primary completion date: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Oct 21, 2016
P1, N=30, Completed, Sponsor: Sun Pharma Advanced Research Company Limited
N=30 --> 57 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2016
- Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Trial primary completion date: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Mar 9, 2016
P1, N=30, Recruiting, Sponsor: Sun Pharma Advanced Research Company Limited
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Trial primary completion date: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Apr 14, 2015
P1, N=30, Recruiting, Sponsor: Sun Pharma Advanced Research Company Limited
Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Apr 2013 --> Mar 2016
- Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Trial initiation date: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Jun 5, 2012
P1, N=30, Recruiting, Sponsor: Sun Pharma Advanced Research Company Limited
Trial primary completion date: Apr 2013 --> Mar 2016 Initiation date: Aug 2011 --> Dec 2011
- Taclantis (paclitaxel injection concentrate for nanodispersion) / Sun Pharma Advanced Research Company
Enrollment open: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination (clinicaltrials.gov) - Aug 22, 2011
P1, N=30, Recruiting, Sponsor: Sun Pharma Advanced Research Company Limited
Initiation date: Aug 2011 --> Dec 2011 Not yet recruiting --> Recruiting